AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
9.06
+0.22 (2.49%)
Aug 13, 2025, 4:00 PM - Market closed
AngioDynamics Employees
AngioDynamics had 675 employees as of May 31, 2025. The number of employees decreased by 73 or -9.76% compared to the previous year.
Employees
675
Change (1Y)
-73
Growth (1Y)
-9.76%
Revenue / Employee
$433,330
Profits / Employee
-$50,360
Market Cap
368.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANGO News
- 7 days ago - AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 17 days ago - AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia - Business Wire
- 22 days ago - AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology - Business Wire
- 4 weeks ago - AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting - Benzinga
- 4 weeks ago - AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth - Business Wire
- 5 weeks ago - AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025 - Business Wire
- 7 weeks ago - AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism - Business Wire